| Risk of progression |
Low | Moderate | High | Very high |
Over an observation period of 3 to 6 months¶, at least 2 of 3 criteria must be present: | 2 or more of the following at the time of diagnosis: |
Kidney function | - Normal or stable (<25% decrease) eGFR over the observation period
| - Normal or stable (<25% decrease) eGFR over the observation period
| - Decrease in eGFR ≥25%, not explained by other causes, at any time during the observation period
| - Serum creatinine ≥1.5 mg/dL (≥133 micromol/L), considered due to active MN
- Decrease in eGFR ≥25% from baseline over the prior 2 years, considered due to active MN
- Severe, disabling, or life-threatening nephrotic syndrome◊
|
Proteinuria | - <4 g/day at the end of the observation period
| - Between 4 and 8 g/day at the end of the observation period
| - >8 g/day at the end of the observation period
or Persistent nephrotic syndromeΔ |
Serum anti-PLA2R antibody levels (only in patients with anti-PLA2R antibody-positive MN) | - Serial titers are persistently low (arbitrarily defined as <50 RU/mL by ELISA) or are decreasing ≥25% by over the observation period
| - Serial titers are <150 RU/mL and stable or increasing by <25%
| - Serial titers are high (arbitrarily defined as ≥150 RU/mL by ELISA) and not declining or are increasing to ≥150 RU/mL
|